JPRN-jRCTs031210704招募中2 期
Clinical trials investigating the efficacy and safety of TM5614 for congenital FGF23-related hypophosphatemic rickets / osteomalacia
ASOU Yoshinori0 个研究点目标入组 5 人开始时间: 2022年3月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.patients over the age of 18 who have given written consent to participate in this study voluntarily (If the patient is 20 years old or younger at the time of consent, written consent must also be obtained from a legal representative.
- •2.patients diagnosed with congenital FGF23-related hypophosphatemic rickets/osteomalacia
- •3.patients with a serum phosphorus level of less than 2.5 mg/dL
- •4.patients with serum intact FGF23 levels greater than or equal to 30 pg/mL
- •5.patients with TmP/GFR less than 2.5 mg/dL
- •6.patients with a corrected serum Ca level less than 10.8 mg/dL
- •7.patients with no history of fracture or pseudofracture (no corrective surgery), and with height greater than -2 SD (male 158 cm, female 148 cm)
排除标准
- •1.patients with congenital FGF23-related hypophosphatemic rickets/osteomalacia who are using or have used the fully human monoclonal antibody burosumab
- •2.patients with active infection or chronic inflammatory disease
- •3.patients with uncontrolled hypertension
- •4.patients with uncontrolled diabetes mellitus.
- •5.patients with kidney disease on dialysis treatment
- •6.patients with a history of or complications of malignant tumors (excluding those with no recurrence or new onset for at least 5 years after treatment)
- •7.patients with complications of cirrhosis (Child-Pugh score class B and C)
- •8.patients with the following abnormalities in liver function
- •patients whose AST and ALT exceed 2.5 times the institutional standard values.
- •patients whose serum bilirubin exceeds 2.5 times the institutional standard
- •9.patients with an eGFR of 30 mL/min/1.73 m2 or more but less than 60 mL/min/1.73 m2
- •10.patients with the following cardiovascular diseases
- •patients with NYHA class II-IV congestive heart failure
- •patients with a history of myocardial infarction in the 6 months prior to enrollment
- •patients with symptomatic arrhythmia that requires treatment
- •11.patients with bleeding tendency: specifically, bleeding time, 5 minutes or more; PT-INR, 3.0 or more; activated partial thromboplastin time, 40 seconds or more
- •12.patients who are receiving prohibited concomitant medications such as anticoagulants and have difficulty in discontinuing such medications
- •13.patients who do not agree to use an appropriate method of contraception while participating in the study
- •14.patients who are participating in other clinical studies
- •15.patients who are considered ineligible by the principal investigator or subinvestigator for other reasons
研究者
相似试验
尚未招募
不适用
Clinical trial to investigate the efficacy and safety of fish skin-derived collagen on wall thickness in the carotid artery and clinical symptom, etc. in healthy adults and subjects with mild carotid artery hypertrophy by a double-blind parallel group comparison desigHealthy adults and subjects with mild carotid artery hypertrophyJPRN-UMIN000026277Kojinkai Medical Corporation Shin-Nihonbashi Ishii clinic120
进行中（未招募）
1 期
Clinical Trial to investigate the efficacy and safety of ANGOCIN® Anti-Infekt N against placebo preventing urinary tract infections in catheterized patientsProphylaxis of catheter-associated chronically inflammatory recurring urinary tract infections in adult patientsMedDRA version: 20.0Level: LLTClassification code 10046544Term: Urinary infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.0Level: LLTClassification code 10007810Term: Catheter related infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-004842-27-DERepha GmbH100
进行中（未招募）
1 期
Clinical trial for examination of efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in the continous prophylaxis of chronically recurring uncomplicated cystitisContinuous prophylaxis of chronically recurring uncomplicated cystitisMedDRA version: 20.1 Level: LLT Classification code 10011786 Term: Cystitis chronic System Organ Class: 100000004862MedDRA version: 21.1 Level: PT Classification code 10063057 Term: Cystitis noninfective System Organ Class: 10038359 - Renal and urinary disordersEUCTR2013-004653-25-DERepha GmbH224
进行中（未招募）
1 期
Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D)Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicineMedDRA version: 26.0Level: LLTClassification code 10060845Term: Diarrhea predominant irritable bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000307-32-DERepha GmbH220
进行中（未招募）
不适用
Clinical study to investigate the efficacy and safety of an estradiol containing cream (0.01 % estradiol) in patients with senile skidermatoporosis stage I and IIEUCTR2011-002464-24-DEDr. August Wolff GmbH & Co. KG Arzneimittel